|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL21A |
Gene summary for METTL21A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL21A | Gene ID | 151194 |
| Gene name | methyltransferase 21A, HSPA lysine | |
| Gene Alias | FAM119A | |
| Cytomap | 2q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8WXB1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151194 | METTL21A | LZE7T | Human | Esophagus | ESCC | 1.37e-07 | 3.16e-01 | 0.0667 |
| 151194 | METTL21A | LZE24T | Human | Esophagus | ESCC | 2.27e-12 | 3.93e-01 | 0.0596 |
| 151194 | METTL21A | LZE6T | Human | Esophagus | ESCC | 1.67e-05 | 2.30e-01 | 0.0845 |
| 151194 | METTL21A | P1T-E | Human | Esophagus | ESCC | 7.06e-07 | 4.28e-01 | 0.0875 |
| 151194 | METTL21A | P2T-E | Human | Esophagus | ESCC | 4.43e-30 | 4.92e-01 | 0.1177 |
| 151194 | METTL21A | P4T-E | Human | Esophagus | ESCC | 3.37e-26 | 7.13e-01 | 0.1323 |
| 151194 | METTL21A | P5T-E | Human | Esophagus | ESCC | 1.36e-04 | 7.59e-02 | 0.1327 |
| 151194 | METTL21A | P8T-E | Human | Esophagus | ESCC | 4.68e-18 | 3.07e-01 | 0.0889 |
| 151194 | METTL21A | P9T-E | Human | Esophagus | ESCC | 6.02e-10 | 2.45e-01 | 0.1131 |
| 151194 | METTL21A | P10T-E | Human | Esophagus | ESCC | 3.36e-20 | 3.35e-01 | 0.116 |
| 151194 | METTL21A | P12T-E | Human | Esophagus | ESCC | 7.52e-30 | 6.03e-01 | 0.1122 |
| 151194 | METTL21A | P15T-E | Human | Esophagus | ESCC | 1.12e-27 | 5.87e-01 | 0.1149 |
| 151194 | METTL21A | P16T-E | Human | Esophagus | ESCC | 2.42e-17 | 3.57e-01 | 0.1153 |
| 151194 | METTL21A | P17T-E | Human | Esophagus | ESCC | 4.04e-04 | 2.03e-01 | 0.1278 |
| 151194 | METTL21A | P19T-E | Human | Esophagus | ESCC | 2.33e-06 | 3.54e-01 | 0.1662 |
| 151194 | METTL21A | P20T-E | Human | Esophagus | ESCC | 3.22e-18 | 4.17e-01 | 0.1124 |
| 151194 | METTL21A | P21T-E | Human | Esophagus | ESCC | 2.87e-21 | 4.96e-01 | 0.1617 |
| 151194 | METTL21A | P22T-E | Human | Esophagus | ESCC | 1.54e-18 | 3.94e-01 | 0.1236 |
| 151194 | METTL21A | P23T-E | Human | Esophagus | ESCC | 1.20e-10 | 2.79e-01 | 0.108 |
| 151194 | METTL21A | P24T-E | Human | Esophagus | ESCC | 3.58e-20 | 3.16e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
| GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
| GO:00064792 | Liver | HCC | protein methylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:00082132 | Liver | HCC | protein alkylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:00180221 | Liver | HCC | peptidyl-lysine methylation | 74/7958 | 131/18723 | 8.46e-04 | 5.06e-03 | 74 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00064797 | Oral cavity | OSCC | protein methylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00082137 | Oral cavity | OSCC | protein alkylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00434142 | Oral cavity | OSCC | macromolecule methylation | 149/7305 | 316/18723 | 1.82e-03 | 8.60e-03 | 149 |
| GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
| GO:001820513 | Oral cavity | LP | peptidyl-lysine modification | 136/4623 | 376/18723 | 3.64e-07 | 1.06e-05 | 136 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL21A | SNV | Missense_Mutation | c.572G>A | p.Cys191Tyr | p.C191Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| METTL21A | insertion | Frame_Shift_Ins | novel | c.556_557insCATATATCCATAT | p.Val186AlafsTer15 | p.V186Afs*15 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| METTL21A | insertion | Nonsense_Mutation | novel | c.555_556insAGAAGGCAAGGATGATA | p.Val186ArgfsTer5 | p.V186Rfs*5 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| METTL21A | SNV | Missense_Mutation | novel | c.489N>G | p.Ile163Met | p.I163M | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| METTL21A | SNV | Missense_Mutation | rs200515055 | c.575G>A | p.Arg192Gln | p.R192Q | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| METTL21A | SNV | Missense_Mutation | rs200515055 | c.575G>A | p.Arg192Gln | p.R192Q | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| METTL21A | SNV | Missense_Mutation | rs372280518 | c.581G>A | p.Arg194His | p.R194H | protein_coding | deleterious(0.03) | possibly_damaging(0.801) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| METTL21A | SNV | Missense_Mutation | novel | c.689N>T | p.Arg230Ile | p.R230I | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| METTL21A | SNV | Missense_Mutation | rs774446965 | c.154N>A | p.Val52Ile | p.V52I | protein_coding | tolerated(0.14) | benign(0.437) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| METTL21A | SNV | Missense_Mutation | rs200515055 | c.575N>A | p.Arg192Gln | p.R192Q | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 151194 | METTL21A | NA | antidepressants | 20643483,17548750 | ||
| 151194 | METTL21A | NA | citalopram | CITALOPRAM | 20643483,17548750 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |